SanBio is a Japanese regenerative medicine company focused on the research, development, manufacturing, and commercialization of cell therapy drugs, with its primary candidate being SB623, an allogeneic mesenchymal stem cell product targeting central nervous system disorders including chronic traumatic brain injury and chronic cerebral infarction. The company has developed proprietary mass-production technology for living cells and operates a licensing business model, partnering with pharmaceutical companies through milestone payments, royalties, and product supply revenues, while also planning direct sales for its conditionally approved product Acugo. SanBio's competitive strengths include allogeneic (off-the-shelf) cell therapy enabling scalable manufacturing and broad patient access, a world-class R&D team led by founding scientist Professor Hideyuki Okano, and a pipeline of five cell therapy candidates addressing high unmet medical needs across neurological and other disease areas.